Kairos Pharma (KAPA) adds CL-741 and outlines ENV-105 trial milestones for 2026
Rhea-AI Filing Summary
Kairos Pharma Ltd. provides a mid-year 2026 update highlighting pipeline expansion and upcoming milestones. The company signed a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for EGFR-mutated lung cancer, part of a treatment landscape valued at $16.2B in 2026. Kairos plans to start a Phase 1 study of CL-741 in EGFR-mutated lung cancer and continue Phase 1 and Phase 2 trials of its lead antibody ENV-105 in non-small cell lung and castrate-resistant prostate cancer. The company notes it is a lean operation with a low monthly burn rate and has secured more than $8 million in non-dilutive funding to support its preclinical and clinical assets.
Positive
- None.
Negative
- None.
Insights
Kairos outlines a busier 2026 pipeline, but with unquantified deal terms.
Kairos Pharma uses this update to frame a broader oncology pipeline. The planned acquisition of CL-741 adds a Phase 1-ready c-MET inhibitor aimed at EGFR-mutated lung and other cancers within a $16.2B 2026 market, expanding beyond ENV-105.
The company emphasizes ongoing Phase 1 and Phase 2 trials for ENV-105 in lung and prostate cancer and signals goals to present safety and efficacy data by Q3 2026. It also highlights over $8 million in non-dilutive funding and a low burn rate, suggesting careful capital use but without detailed cash runway.
Planned milestones—initiating CL-741 Phase 1, advancing ENV-105 trials, and pursuing collaborations by end of Q2/beginning of Q3 2026—could shape future value, yet actual impact will depend on trial results and successful closing of the CL-741 transaction and partnerships.
8-K Event Classification
Key Figures
Key Terms
term sheet financial
c-MET kinase inhibitor medical
EGFR-mutated lung cancer medical
non-dilutive funding financial
Phase 2 clinical trial medical
forward-looking statements regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 8.01. | Other Events. |
On June 4, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release providing a summary of the Company’s achievements for the first half of 2026, as well as key milestones the Company expects to reach by the end of 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section. The information in this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statement and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 4, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IPOWER, INC. | ||
| Dated: June 4, 2026 | ||
| By: | /s/ John S. Yu | |
| Name: | John S. Yu | |
| Title: | Chief Executive Officer | |
| 3 |
Exhibit 99.1
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
LOS
ANGELES,
To our valued Kairos Pharma Shareholders,
As we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates to our existing pipeline. We announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. The Company will be acquiring the worldwide rights for a highly differentiated, clinical-stage oncology asset targeting non-small cell lung cancer (NSCLC) and esophageal and gastric cancer: CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
CL-741 is a Phase 1-ready therapeutic candidate targeting EGFR-mutated lung cancer, a treatment landscape valued at an estimated $16.2B in 2026 (Future Market Insights). We intend to utilize Kairos’s proven expertise in developing drug-resistance therapeutics and establishing strong clinical partnerships to accelerate CL-741’s pathway for patients with EGFR-mutant and c-MET-driven lung cancers.
CL-741 will add to our already existing portfolio of exciting targets, including ENV-105, KROS-201, KROS-102 and ENV-205. We remain committed to seeing these therapeutics through the clinical system alongside our partners utilizing non-dilutive clinical funding as much as possible.
Other highlights from this quarter include:
| ● | Kairos Pharma Presented at the 3rd Annual DealFlow Discovery Conference | |
| ● | Our CSO Dr. Neil Bhowmick Interviewed with the RedChip Small Stocks Big Money Show | |
| ● | Kairos Pharma participated in The Scientist’s two-day symposium on Emerging Therapeutic Strategies in Oncology |
As Kairos continues to showcase the potential of our drug candidates, we anticipate the following key milestones for the rest of 2026, including:
| ● | The initiation of a Phase 1 study with CL-741 targeting EGFR-mutated lung cancer | |
| ● | Continued execution in the second phase of our randomized clinical trial of ENV-105 in prostate cancer, with more trial sites expected to be announced before the end of the year | |
| ● | Continued execution of our Phase 1 clinical trial of ENV-105 in non-small cell lung cancer, with the goal of announcing key safety and efficacy results by Q3 2026 | |
| ● | Presenting key data on our ongoing programs at national scientific meetings | |
| ● | Working to develop key collaborations with pharmaceutical companies that test the synergy of ENV-105 with oncology drugs for prostate cancer by end of Q2/beginning of Q3 2026 |
Kairos Pharma is a lean operation with a low monthly burn rate and more than $8 million dollars already in non-dilutive funding for the preclinical and clinical assets under our management. Additionally, our strategic relationship partner, the Cedars-Sinai Medical Center, recently announced a CRO consortium leveraging the efficiencies of partner institutes such as the Mayo Clinic, Stanford, The Cleveland Clinic, Rutgers and more to extend the reach of innovative therapies, like our own, across diverse communities.
Our conviction in the transformative potential of our therapeutic pipeline remains unwavering. Built on proprietary science pioneered by our executive team, we believe these treatments will deliver lasting clinical value by successfully targeting and halting the progression of resistance development in complex cancers.
We
deeply appreciate the ongoing collaboration of our partners and the trust of our investors. As we scale our scientific capabilities,
our primary focus remains on generating sustainable, near- and long-term shareholder returns. We look forward to keeping you informed
of our developmental milestones in the quarters ahead.
Sincerely,
John Yu, M.D.
CEO
Kairos Pharma
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our ability to complete the CL-741 acquisition; our success in completing newly initiated clinical trials, commence new trials and fund such trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s Annual Report on Form 10-K and other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.
Contact:
CORE IR
investors@kairospharma.com
https://investors.kairospharma.com/overview/default.aspx